Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report.

Autor: Palomar-Ciria N; Psychiatry Service, Complejo Asistencial de Soria, Soria., Migoya-Borja M; Department of Psychiatry, Jiménez Díaz Foundation., Cegla-Schvartzman F; Department of Psychiatry, Jiménez Díaz Foundation., Ovejero S; Department of Psychiatry, Jiménez Díaz Foundation., Alvarez-Garcia R; Department of Psychiatry, Rey Juan Carlos Hospital, Móstoles, Madrid., Bello HJ; Department of Applied Mathematics, Universidad de Valladolid, Soria., Baca-García E; Department of Psychiatry, Jiménez Díaz Foundation.; Department of Psychiatry, Rey Juan Carlos Hospital, Móstoles, Madrid.; Universidad Autónoma de Madrid, Facultad de Medicina.; Insituto de Investigación Sanitaria Fundación Jiménez Díaz.; Department of Psychiatry, General Hospital of Villalba, Villalba.; Department of Psychiatry, University Hospital Infanta Elena, Valdemoro.; CIBERSAM (Centro de Investigación en Salud Mental), Carlos III Institute of Health, Madrid, Spain.; Universidad Católica del Maule, Talca, Chile.
Jazyk: angličtina
Zdroj: International clinical psychopharmacology [Int Clin Psychopharmacol] 2021 Mar 01; Vol. 36 (2), pp. 97-100.
DOI: 10.1097/YIC.0000000000000345
Abstrakt: Fifty-one patients suffering an acute episode of schizophrenia and treated with aripiprazole long-acting injectable (ALAI) were chosen to elaborate an observational study in two in-patient units in Spain, in order to examine the effects of early administration during a hospital admission. When treatment with ALAI is administered in the first week of admission (in 31 patients, 60.78%), hospitalization time is significantly reduced, 12.1 days on average. It can be concluded that ALAI is an effective treatment for these patients. Analysis in economic terms and comparison with other LAI antipsychotics are interesting lines for further research.
(Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: